MX2013008870A - Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazoli n-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion. - Google Patents

Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazoli n-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion.

Info

Publication number
MX2013008870A
MX2013008870A MX2013008870A MX2013008870A MX2013008870A MX 2013008870 A MX2013008870 A MX 2013008870A MX 2013008870 A MX2013008870 A MX 2013008870A MX 2013008870 A MX2013008870 A MX 2013008870A MX 2013008870 A MX2013008870 A MX 2013008870A
Authority
MX
Mexico
Prior art keywords
undecan
dimaleate
quinazolin
diaza
chlor
Prior art date
Application number
MX2013008870A
Other languages
English (en)
Inventor
Peter Sieger
Waldemar Pfrengle
Markus Ostermeier
Guenther Huchler
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2013008870A publication Critical patent/MX2013008870A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con un compuesto de fórmula (I), que tiene propiedades farmacológicas valiosas, en particular un efecto inhibidor en la transducción de señal mediada por tirosina quinasas, para métodos para producir de forma estereoselectiva tales compuestos, en particular formulaciones farmacológicas adecuadas para inhalación, y para el uso de las mismas para tratar enfermedades, en particular enfermedades tumorales, hiperpiasia prostática benigna y enfermedades de los pulmones y tractos respiratorios. (ver Fórmula).
MX2013008870A 2011-02-01 2012-01-27 Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazoli n-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion. MX2013008870A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11152895 2011-02-01
PCT/EP2012/051298 WO2012104206A1 (de) 2011-02-01 2012-01-27 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-chinazolin-6- yloxy]-1,4-diaza-spiro[5.5]undecan-5-on dimaleat, dessen verwendung als arzneimittel und dessen herstellung

Publications (1)

Publication Number Publication Date
MX2013008870A true MX2013008870A (es) 2013-08-14

Family

ID=43896655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008870A MX2013008870A (es) 2011-02-01 2012-01-27 Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazoli n-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion.

Country Status (23)

Country Link
US (2) US8853225B2 (es)
EP (1) EP2670736B1 (es)
JP (1) JP2014504619A (es)
KR (1) KR20140011330A (es)
CN (1) CN103608336A (es)
AP (1) AP3531A (es)
AR (1) AR085056A1 (es)
AU (1) AU2012213556A1 (es)
BR (1) BR112013019416A2 (es)
CA (1) CA2826193A1 (es)
CL (1) CL2013002031A1 (es)
CO (1) CO6781555A2 (es)
EA (1) EA023573B1 (es)
EC (1) ECSP13012847A (es)
GE (1) GEP20156423B (es)
IL (1) IL227534A0 (es)
MA (1) MA34845B1 (es)
MX (1) MX2013008870A (es)
PE (1) PE20141012A1 (es)
SG (1) SG192216A1 (es)
TN (1) TN2013000323A1 (es)
UY (1) UY33889A (es)
WO (1) WO2012104206A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289881A1 (de) 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
JP2014504619A (ja) 2011-02-01 2014-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンジマレアート、その医薬としての使用及びその製造方法
MX2014009033A (es) 2012-02-09 2014-10-17 Boehringer Ingelheim Int Metodo para la sintesis estereoselectiva de 9-hidroxi-5-oxo-1,4-di aza-espiro[5,5]undecanos 1,4-protegidos.
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
AU2014361633B2 (en) * 2013-12-12 2017-07-20 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Quinazoline derivative
CN105017164A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 含新型苯并喹唑啉和邻位氯结构的酪氨酸激酶抑制剂及用途
CN105130913A (zh) * 2015-08-25 2015-12-09 佛山市赛维斯医药科技有限公司 一类多取代的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN109503579A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-9-甲酸基酯的制备方法
CN109485648A (zh) * 2018-12-17 2019-03-19 无锡合全药业有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-8-甲酸基酯的制备方法
CN109608470A (zh) * 2018-12-17 2019-04-12 上海药明康德新药开发有限公司 叔丁基-9-氧亚基-2,5,8-三氮杂螺[3.5]壬烷-2-甲酸基酯的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
CN1642552B (zh) * 2002-03-30 2010-05-12 贝林格尔英格海姆法玛两合公司 作为酪氨酸激酶抑制剂的4-(n-苯氨基)-喹唑啉/喹啉
EP1817310A1 (en) 2004-09-17 2007-08-15 OSI Pharmaceuticals, Inc. (spirocyclylamido) aminothiophene compounds as c-kit proto-oncogene inhibitors
CA2631813A1 (en) 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
BRPI0818687A2 (pt) 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
EA019709B1 (ru) 2008-02-07 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Спирогетероциклы и их применение в качестве лекарственных средств
US8629153B2 (en) * 2008-09-03 2014-01-14 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
EP2289881A1 (de) 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
JP2014504619A (ja) 2011-02-01 2014-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンジマレアート、その医薬としての使用及びその製造方法

Also Published As

Publication number Publication date
EP2670736B1 (de) 2017-03-15
CL2013002031A1 (es) 2013-12-27
ECSP13012847A (es) 2014-09-30
UY33889A (es) 2012-08-31
AU2012213556A1 (en) 2013-08-22
US20140371226A1 (en) 2014-12-18
BR112013019416A2 (pt) 2019-09-24
SG192216A1 (en) 2013-09-30
AP2013006989A0 (en) 2013-07-31
AP3531A (en) 2016-01-13
PE20141012A1 (es) 2014-09-10
NZ613917A (en) 2015-08-28
CO6781555A2 (es) 2013-10-31
WO2012104206A1 (de) 2012-08-09
US8853225B2 (en) 2014-10-07
GEP20156423B (en) 2016-01-11
JP2014504619A (ja) 2014-02-24
US20130030003A1 (en) 2013-01-31
CA2826193A1 (en) 2012-08-09
US8906931B1 (en) 2014-12-09
EA023573B1 (ru) 2016-06-30
MA34845B1 (fr) 2014-01-02
CN103608336A (zh) 2014-02-26
IL227534A0 (en) 2013-09-30
KR20140011330A (ko) 2014-01-28
EA201300872A1 (ru) 2014-01-30
TN2013000323A1 (en) 2015-01-20
AR085056A1 (es) 2013-08-07
EP2670736A1 (de) 2013-12-11
WO2012104206A9 (de) 2013-11-21

Similar Documents

Publication Publication Date Title
TN2013000323A1 (en) 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof
MY155653A (en) Triazine compounds as p13 kinase and mtor inhibitors
GEP201706707B (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
MA32137B1 (fr) Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour leur fabrication
EA023222B8 (ru) Пиразолилхиноксалиновые ингибиторы киназы
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
TW200730508A (en) Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2010008638A (es) Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas.
AU2009282962A8 (en) Compounds as kinase inhibitors
NZ630489A (en) Bicyclic pyrazinone derivatives
MX2013002384A (es) Compuestos quinazolina y metodos para utilizarlos.
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
GB201302704D0 (en) Therapeutic compounds
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX2009007610A (es) Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
BR112018004347A2 (pt) derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida
TW200640904A (en) Quinazoline derivatives
MX2012001089A (es) Procedimientos para la sintesis estereoselectiva de heterociclos biciclicos.
WO2009007753A3 (en) 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal